Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia

Weber, Daniela; Calderwood, Stephen B.; Karchmer, Adolf W.; Pennington, James E.

doi:10.1128/aac.31.6.876

Cited by 12 publications

(4 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reasons for these findings could not be determined. The cure rates are similar to those reported in earlier studies of cefamandole in the therapy of pneumonia (30)(31)(32). Rapid defervescence and prompt clinical responses were noted in the majority of patients, regardless of treatment group, with a mean duration of therapy needed of only 5.1 days.…”

Section: -4)supporting

confidence: 84%

Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia

Williams

Perri

Zervos

1994

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

In a randomized prospective study ampicillin/sulbactam and cefamandole were compared in the therapy of patients hospitalized with community acquired pneumonia. Patients receiving ampicillin/sulbactam (n = 37) and cefamandole (n = 38) were similar with respect to age (mean age 70 vs. 76 years respectively), clinical characteristics, severity of illness and underlying disease. Pathogens isolated from patients in the cefamandole and ampicillin/sulbactam group, respectively, were Streptococcus pneumoniae (7 vs. 7 patients), Haemophilus parainfluenzae (7 vs. 6 patients), Haemophilus influenzae (5 vs. 5 patients), Staphylococcus aureus (5 vs. 4 patients), Escherichia coli (4 vs. 4 patients), Klebsiella pneumoniae (3 vs. 3 patients), Enterobacter spp. (2 vs. 3 patients), Moraxella catarrhalis (1 vs. 2 patients), and organisms of the oral flora (4 vs. 3 patients). The rate of resistance to penicillin was 80%, to clindamycin 76%, to erythromycin 45%, to ampicillin 43%, and to cefazolin 18%. Overall successful treatment rates of 81% for cefamandole and 97% for ampicillin/sulbactam (p = 0.05) were observed. Both cefamandole and ampicillin/sulbactam were shown to be effective agents for therapy of community acquired pneumonia; however ampicillin/sulbactam demonstrated superior overall clinical efficacy.

show abstract

Section: -4)supporting

confidence: 84%

Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia

Williams

Perri

Zervos

1994

Eur. J. Clin. Microbiol. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…The literature review for the period 1981–2008 provided only 19 acceptable articles relevant to the antibiotic management of CAP 277 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 . [Ib] [Ib] [Ib] [Ib] [II] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] [Ib] The remainder were rejected for the following reasons: inadequately powered studies or a retrospective design,102 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 non-blinded/non-randomised studies,274 401 402 403 404 405 antibiotic not available in the UK or withdrawn,357 361 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 study population or management unrepresentative of normal clinical practice in the UK,377 442 …”

Section: Section 8 Antibiotic Managementmentioning

confidence: 99%

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

Lim

Baudouin²,

George³

et al. 2009

Thorax

1,178

1,073

View full text Add to dashboard Cite

“…It has been almost 70 years since the first dose of penicillin was administered to a patient [1,2], however optimal durations of antibiotic therapy continue to be a topic of debate. Traditional durations of therapy for bacterial infections generally stem from clinical trials funded from pharmaceutical companies and have been carried forward for decades [2][3][4][5][6][7][8][9][10][11][12][13][14]. Evidence supporting traditional durations of therapy has come under greater scrutiny recently as a multitude of studies supporting shorter antibiotic courses have emerged [15][16].…”

Section: Introductionmentioning

confidence: 99%

Defining effective durations of antibiotic therapy for community-acquired pneumonia and urinary tract infections in hospitalized children

Wingler

2022

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of reviewCommunity-acquired pneumonia (CAP) and urinary tract infections (UTI) are two common childhood infections often leading to hospital admission. National guidelines for CAP and UTI in children recommend durations of antibiotic therapy of 10 days and 7–14 days, respectively. Due to concerns of rising antimicrobial resistance and an increased awareness of harms associated with prolonged courses of antibiotics, there is a renewed emphasis on reevaluating commonly prescribed durations of antibiotic therapy across bacterial infections. We describe recent clinical trials and observational studies evaluating durations of therapy for CAP and UTI in adults and children and translate the findings to our suggested approach for selecting durations of antibiotic therapy in hospitalized children.Recent findingsThere is a growing body of evidence, primarily in adults, that shorter durations of therapy than are commonly prescribed are just as effective as longer durations for CAP and UTIs.SummaryCombining clinical trial data from adults with available data in children, we believe it is reasonable to consider 5 days of therapy for CAP, 3–5 days of therapy for cystitis, and 7 days of therapy for pyelonephritis for most hospitalized children with uncomplicated infections.

show abstract

Ampicillin versus cefamandole as initial therapy for community-acquired pneumonia

Abstract: One hundred seven patients with community-acquired pneumonia thought to be of bacterial etiology by the admitting physician but whose initial sputum Gram

Cited by 12 publications

References 48 publications

Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia

Randomized comparative trial with ampicillin/sulbactam versus cefamandole in the therapy of community acquired pneumonia

BTS guidelines for the management of community acquired pneumonia in adults: update 2009

Defining effective durations of antibiotic therapy for community-acquired pneumonia and urinary tract infections in hospitalized children

Contact Info

Product

Resources

About